Keenova Therapeutics and Par Health
This role involves evaluating extractable and leachable studies for pharmaceutical products, with responsibilities including analytical method development, validation, and analysis of nitrosamine impurities. The position also requires calibration and maintenance of analytical instruments, and preparation and review of laboratory documents related to nitrosamine assessment.
Keenova Therapeutics and Par Health are the successor entities formed after Mallinckrodt's merger with Endo; Keenova Therapeutics focuses on specialty therapeutics across rare and unaddressed conditions (immunology, urology, hepatology, ophthalmology, orthopedics, critical care), while Par Health develops high-quality generics, sterile injectables, and active pharmaceutical ingredients (APIs) with a robust U.S.-advantaged manufacturing network.
Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader
Aug 1, 2025
With merger in the books, Mallinckrodt and Endo rebrand as Keenova and spin off Par Health
Nov 11, 2025
Judge Says 'Error' Kept Mallinckrodt Execs In Investor Suit
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Keenova Therapeutics and Par Health.
Keenova Therapeutics and Par Health didn’t post a salary, so this is our estimate from similar listings.
Mallinckrodt Names Christiana Stamoulis President and CFO
Aug 6, 2025
Executive- Analytical development
Sun Pharmaceutical Industries Limited
Lead Scientist-DP Analytical Development- OSD
Syngene International Limited
Junior Analytical Scientist
Syngene International Limited
Manager/Group Leader- E&L
Eurofins
Product Chemistry Associate Scientist
Eurofins
Research Associate II
Baxter International